Analyst Mitchell Kapoor of H.C. Wainwright reiterated a Buy rating on CytomX Therapeutics, retaining the price target of $5.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Mitchell Kapoor has given his Buy rating due to a combination of factors surrounding CytomX Therapeutics’ progress with their CX-2051 drug candidate. The company is advancing its Phase 1 expansion cohorts with promising data expected in the first quarter of 2026. The upcoming Phase 2 trial in fourth-line colorectal cancer (CRC) is anticipated to start in the first half of 2026, with dose selections aligned with FDA guidelines, indicating a well-structured clinical development plan.
Moreover, the interim results from the Phase 1 study have shown a positive efficacy signal, with the drug achieving a 28% confirmed overall response rate (ORR) across various dose levels, and a particularly strong 43% ORR at the highest dose. The median progression-free survival (mPFS) of 5.8 months is considered clinically meaningful, especially as higher doses have shown potential for greater efficacy. Additionally, the safety profile appears manageable, with no dose-limiting toxicities and a proactive approach to managing side effects like diarrhea. These factors collectively support the potential for CX-2051 to make significant strides in CRC treatment, justifying the Buy rating.
In another report released on August 8, Oppenheimer also reiterated a Buy rating on the stock with a $7.00 price target.